Technology Overview Soluble epoxide hydrolase (sEH) inhibition is a therapeutic target for a large number of cardiovascular diseases. Disrupting dimerization of sEH reduces hydrolase activity and shifts the sub-cellular localization of sEH to peroxisomes. The current technology is a split-firefly luciferase assay that not only measures disruption of sEH dimerization as a means of inhibition, but also acts as a high throughput screen for small molecules that could inhibit sEH dimerization.
Publication Nelson JW, et. Al, “Soluble epoxide hydrolase dimerization is required for hydrolase activity. J Biol Chem. 2013 Mar 15;288(11):7697-7703. Link
Licensing Opportunity This technology is available for licensing.